Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-02
2005-08-02
Turner, Sharon L. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S324000, C530S325000, C530S326000, C530S327000
Reexamination Certificate
active
06924266
ABSTRACT:
The present invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using peptides derived from the amino acid sequences of neural thread proteins and related molecules.
REFERENCES:
patent: 5830670 (1998-11-01), de la Monte et al.
patent: 5948634 (1999-09-01), de la Monte et al.
patent: 5948888 (1999-09-01), de la Monte et al.
patent: 6071705 (2000-06-01), Wands et al.
patent: WO 98 38204 (1998-09-01), None
patent: WO 99/19347 (1999-04-01), None
patent: WO 00 34477 (2000-06-01), None
patent: WO 00/58495 (2000-10-01), None
patent: WO 00/63230 (2000-10-01), None
patent: WO 02 34915 (2002-05-01), None
patent: WO 02 074323 (2002-09-01), None
patent: WO 02 092115 (2002-11-01), None
Wells (Sept. 18, 1990) “Additivity of Mutational Effects in Proteins.” Biochemistry 29(37): 8509-8517.
Ngo et al. (Mar. 2, 1995) “The Protein Folding Problem and Tertiary Structure Predication, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox” pp. 433-506.
Bork (2000) “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle.” Genome Research 10:398-400.
Skolnick and Fetrow (2000) “From gene to protein structure and function: novel applications of computational approaches in th genomic era.” Trends in Biotech. 18(1): 34-39.
Doerks et al., (Jun. 1998) “Protein annotation: detective work for function prediction.” Trends in Genetics 14(6): 248-250.
Smith and Zhang (Nov. 1997) “The challenges of genome sequence annotation or ‘The devil is in the details’.” Nature Biotechnology 15:1222-1223.
Brenner (Apr. 1999) “Errors in genome annotation.” Trends in Genetics 15(4): 132-133.
Bork and Bairoch (Oct. 1996) “Go hunting in sequence databases but watch out for the traps.” Trends in Genetics 12(10): 425-427.
de la Monte et al. (Jun. 1996) “Modulation of neuronal thread protein expression with neuritic sprouting: relevance to Alzheimer's disease.” Journal of the Neurological Sciences 138(1-2): 26-35.
de la Monte et al.: “Characterization of the AD7C-NTP cDNA Expression in Alzheimer's Disease and Measurement of a 41-kD Protein in Cerebrospibal Fluid” Journal of Clincial Investigation, vol. 100, No. 12, Dec. 15, 1997, pp. 3093-3104.
International Search Report issued in PCT/CA02/00759, date of mailing Sep. 11, 2003.
Sijits, et al.,Immunodominant Mink Cell Focus-Inducing Murine Leukemia Virus(MuLV)-Encoded CTL Epitope, Identified by its MHC Class I-Binding Motif, Explains MuLV-Type Specificity of MCF-Directed Cytotoxic T Lymphocytes, Journal of Immunology, The Williams Y Wilkins Co., Baltimore, vol. 152, 1994, pp. 106-116.
Hunton & Williams LLP
Nichols Christopher James
Nymox Corporation
Turner Sharon L.
LandOfFree
NTP-peptides and method for removal of tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with NTP-peptides and method for removal of tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NTP-peptides and method for removal of tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3476680